We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+6.99%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$184M
AUM Growth
+$42.5M
Cap. Flow
+$36.1M
Cap. Flow %
19.61%
Top 10 Hldgs %
31.33%
Holding
99
New
45
Increased
12
Reduced
8
Closed
29

Top Buys

1
ZBH icon
Zimmer Biomet
ZBH
+$5.07M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.94M
3
CYBX
CYBERONICS INC
CYBX
+$4.32M
4
AGN
Allergan Inc
AGN
+$4.15M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$4.09M

Top Sells

1
MDVN
MEDIVATION, INC.
MDVN
+$6.17M
2
COO icon
Cooper Companies
COO
+$5.42M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.24M
4
BSX icon
Boston Scientific
BSX
+$5.11M
5
INSM icon
Insmed
INSM
+$4M

Sector Composition

1 Healthcare 63.11%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INO icon
76
PUT
Inovio Pharmaceuticals
INO
$92.1M
– –
-8,333
Closed -$1.08M
INSM icon
77
Insmed
INSM
$23.5B
– –
-200,000
Closed -$4M
REGN icon
78
Regeneron Pharmaceuticals
REGN
$70.9B
– –
-7,500
Closed -$2.12M
SPY icon
79
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
– –
-75,000
Closed -$14.7M
TEVA icon
80
Teva Pharmaceuticals
TEVA
$37.3B
– –
-100,000
Closed -$5.24M
VTRS icon
81
CALL
Viatris
VTRS
$20.1B
– –
-150,000
Closed -$7.73M
RVNC
82
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-20,000
Closed -$680K
ICPT
83
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-10,000
Closed -$2.37M
INFI
84
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-75,000
Closed -$956K
AMAG
85
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-100,000
Closed -$2.07M
CYNO
86
DELISTED
Cynosure, Inc. Class A
CYNO
– –
-50,000
Closed -$1.06M
DYAX
87
DELISTED
DYAX CORPORATION
DYAX
– –
-65,000
Closed -$624K
GEVA
88
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-30,000
Closed -$3.14M
NPSP
89
CALL
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-50,000
Closed -$1.65M
NPSP
90
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-40,000
Closed -$1.32M
RNA
91
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
– –
-175,000
Closed -$2.21M
COV
92
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
– –
-30,000
Closed -$2.71M
BDSI
93
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-300,000
Closed -$3.62M
OREX
94
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-25,000
Closed -$1.54M
AIRM
95
DELISTED
Air Methods Corp
AIRM
– –
-20,000
Closed -$1.03M
MDVN
96
DELISTED
MEDIVATION, INC.
MDVN
– –
-160,000
Closed -$6.17M
ANAC
97
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-150,000
Closed -$2.66M
1 2 3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2014 Portfolio in Review

As of Q3 2014, Ghost Tree Capital held 99 positions worth $184M, up 30% from $142M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Ghost Tree Capital deployed $36.1M of net new capital in Q3 2014, opening 45 new positions and adding to 12 existing holdings. Its largest new stake was Zimmer Biomet: 51,500 shares worth $5.03M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 60% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Allergan plc, an estimated $3.36M trimmed.

  • Ghost Tree Capital's largest Q3 2014 buy was Zimmer Biomet: 51,500 shares worth $5.03M.
  • Ghost Tree Capital added most to TherapeuticsMD in Q3 2014, an estimated $2.52M increase.
  • Ghost Tree Capital's biggest Q3 2014 reduction was Allergan plc, cutting an estimated $3.36M.
  • Ghost Tree Capital fully exited MEDIVATION, INC. in Q3 2014, selling an estimated $6.17M.
  • Ghost Tree Capital's ten largest holdings make up 31% of its $184M portfolio in Q3 2014.
  • Ghost Tree Capital opened 45 new positions and closed 29 in Q3 2014.
  • Ghost Tree Capital's portfolio value rose 30% quarter-over-quarter to $184M.

Based on Ghost Tree Capital's 13F filing for Q3 2014, filed 14 Nov 2014.